Biotheryx to Present Preclinical Data for Its Dual Protein D

/PRNewswire/ -- Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs)...

Related Keywords

Illinois , United States , Chicago , American , Ikaros Aiolos , Aparajita Hoskote Chourasia , Philippe Drouet , Leah Fung , Linkedin , American Society Of Clinical Oncology , Biotheryx Inc , Drug Administration , Prnewswire Biotheryx Inc , Development For The Treatment Of Hematologic , Beneficial Immunomodulatory Properties , Durable Dual Degradation , Vitro Along , Beneficial Immunomodulatory , Support Ongoing Phase , Solid Tumor , Clinical Oncology , Annual Meeting , Chief Scientific Officer , Chief Executive Officer , Hematologic Malignancies , Myelodysplastic Syndromes ,